The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein
Status:
Unknown status
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
In order to reevaluate safety and efficacy of human urinary kallikrein in treating acute
cerebral infarction ,a multi-center, open label , single group study was designed. Expect to
enroll 60 sites and 2186 subjects. Subjects will receive kallikrein treatment according to
real clinical practice (suggest above 14days treatment) and 90 days follow up